(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 May 2010 (20.05.2010)

PCT

(10) International Publication Number
WO 2010/056205 A9

(51) International Patent Classification:
C07D 257/02 (2006.01) *A61B 5/055* (2006.01)
A61K 31/555 (2006.01)

(21) International Application Number:
PCT/SG2009/000418

(22) International Filing Date:
11 November 2009 (11.11.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/113,277 11 November 2008 (11.11.2008) US

(71) Applicants *(for all designated States except US)*: **NANYANG TECHNOLOGICAL UNIVERSITY** [SG/SG]; 50 Nanyang Avenue, Singapore 639798 (SG). **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10, Connexis, Singapore 138632 (SG).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BATES, Roderick, Wayland** [GB/SG]; Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798 (SG). **GOLAY, Xavier** [CH/GB]; UCL Institute of Neurology, National Hospital for Neurology & Neurosurgery, Queen Square 8-11, London WC1N 3BG (GB). **YANG, Changtong** [CN/SG]; Singapore Bioimaging Consortium, 11 Biopolis Way, #01-02, Singapore 138667 (SG).

(74) Agent: **YU SARN AUDREY & PARTNERS**; 17 Upper Circular Road, #03-00 Juta Building, Singapore 058415 (SG).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

[Continued on next page]

(54) Title: INTRAVASCULAR CONTRAST AGENTS




Figure 2

(57) Abstract: The present invention provides Gd-chelates modified so as to comprise an amino acid unit attached to the chelate via a linker group suitably selected from C2-4alkylene and C3-5alkynylene, and the use of such chelates as an intravascular contrast agent for MRI. Embodiments demonstrate enhanced relaxivity and good levels of signal enhancement.

WO 2010/056205 A9

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))*

(48) Date of publication of this corrected version:
14 October 2010

(15) Information about Correction:
see Notice of 14 October 2010